The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Blinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial
|
Results from the third interim efficacy analysis of the phase III ECOG-ACRIN E1910 trial (NCT02003222) evaluating blinatumomab in combination with standard consolidation chemotherapy in adult patients with BCR::ABL1 negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in measurable residual disease (MRD) negative remission were published in The New England Journal of Medicine by Litzow et al.1
|
| Key learnings |
|
A total of 224 patients with BCR::ABL1-negative B-ALL in MRD negative remission were included in the analysis.
|
|
At a median follow-up of 43 months, the 3-year overall survival was significantly improved in the blinatumomab group vs chemotherapy alone group (85% vs 68%; hazard ratio for death, 0.41; 95% confidence interval [CI]: 0.23–0.73; p = 0.002). |
|
The 3-year relapse-free survival improved in the blinatumomab group vs chemotherapy alone group (80% vs 64%; hazard ratio for relapse or death, 0.53; 95% CI: 0.32–0.87). |
|
The incidence of treatment-related Grade ≥3 neurologic or psychiatric adverse events was higher in the blinatumomab group vs chemotherapy alone group (23% vs 5%; p < 0.001). |
|
The results suggest an overall survival benefit of the addition of blinatumomab to consolidation chemotherapy in adult patients with BCR::ABL1-negative B-ALL in MRD-negative remission; a longer international follow-up is needed to further confirm. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
